Guerrini M. , Zhang Z., Shriver Z., et al. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A.2009 ;106(40): 16956-16961.
2.
Kishimoto TK , Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457-2467.
3.
Guerrini M., Beccati D., Shriver Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008;26(6): 669-675.
4.
Qian Y., Pan J., Zhou X., et al. Heparin and oversulfated heparin by-products induce thrombin generation through contact system activation in plasma of patients with HIT . Clin Appl Thromb Hemost. IN PRESS.
5.
Qian Y., Pan J., Zhou X., et al. Contaminated heparin-affected patient plasmas are associated with activated contact systems. Clin Appl Hemost. IN PRESS.
6.
Qian Y., Pan J., Zhou X., et al. Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation. IN PRESS.
7.
Adiguzel C., Bansal V., Litinas E., et al. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Clin Appl Thromb Hemost.2009;15(2):145-151.
8.
Pan J., Qian Y., Zhou X., et al. Identification of chemically sulfated/desulfated glycosaminoglycans in contaminated heparins and development of a simple assay for the detection of most contaminants in heparin. Glycobiol Insights. 2010;2:1-12.
9.
FDA.Information on adverse event reports and heparin. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm112669.htm; 2009.
